28
AUG
2018

NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit

Posted By :
Comments : Off
BETHESDA, Md., August 28, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio is presenting at 8:00 pm Wednesday evening, August 29, at the Immuno-Oncology Summit being held at the Seaport World Trade Center, 1 Seaport Boulevard in Boston, Massachusetts....
Read More
31
MAY
2018

NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

Posted By :
Comments : Off
BETHESDA, Md., May 31, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will...
Read More
29
MAY
2018

NW Bio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Posted By :
Comments : Off
Median survival of top 100 patients is 40.5 months, Median survival of all 331 patients is 23.1 months, Longest survivors have exceeded 7 years BETHESDA, Md., May 29, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L...
Read More
01
MAY
2018

NW Bio Releases Vote Tallies From Special Shareholder Meeting

Posted By :
Comments : Off
Large Voter Turn-Out and Landslide Approval Of All Proposals   BETHESDA, Md., May 1, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the vote tallies for the three proposals on the ballot at its Special Meeting of Shareholders held last Friday afternoon in Washington, DC. Voter turnout was 74% of all...
Read More
30
APR
2018

NW Bio Announces Additional Funding

Posted By :
Comments : Off
 CEO Increases Year to Date Funding to $5.4 Million   BETHESDA, Md., April 30, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, increased her funding to the Company by $1 million, reaching a total of $5.4 million this year to date. On April 26, 2018, the Company and Ms. Powers entered into a...
Read More